Nature 561 , 492497 (2018)
Novo Nordisk received FDA approval for its semaglutide-based GLP-1 products, Ozempic for diabetes and Wegovy for weight loss, in December 2017 and June 2021, respectively
Many patients report: Feeling effects more quickly Increased nausea Greater dehydration Reduced tolerance Summer often includes: Pool parties Vacations Cookouts Social gatherings This makes alcohol-related side effects more noticeable
Clear instructions covering drug information, storage, temperature handling, and injection technique
The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying
But as of right now, the guidelines do not say like, you have to have labs first, so to assess metabolic and hormone status